Bronchopulmonary dysplasia, a type of chronic lung disorder, affects newborns, mostly premature and infants. Lungs and bronchi are damaged at the neonatal phase which causes destruction of tiny air sacs known as alveoli. Babies are not born with the disease. The condition is developed when premature infants need aid to breathe for a longer period, leading to inflammation and lung scarring. Infants with this disease exhibit signs and symptoms such as rapid breathing and faster heart rate. The disease is life threatening however, the severity of the disease varies.
The global bronchopulmonary dysplasia treatment market is expected to expand at a steady CAGR during the forecast period. According to the Journal of Clinical Medicine, 10,000 to 15,000 new cases of the disorder are reported each year in the U.S. alone. High prevalence of the diseases is expected to drive the global bronchopulmonary dysplasia treatment market during the forecast period. According to the WHO, 15 million babies are born preterm which is another factor contributing to the growth of the market. Furthermore, government initiatives, favorable reimbursement policies, launch of novel drugs, strong pipeline, rising premature birth cases, and increase in health care expenditure are factors likely to propel the global bronchopulmonary dysplasia treatment market during the forecast period. Long-term side effects of drugs, high cost of treatment, and lack of awareness in developing countries are factors anticipated to restrain the global market during the forecast period.

Market Analysis and Insights: Global Bronchopulmonary Dysplasia Market
The global Bronchopulmonary Dysplasia market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bronchopulmonary Dysplasia market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bronchopulmonary Dysplasia market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bronchopulmonary Dysplasia market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bronchopulmonary Dysplasia market.

Global Bronchopulmonary Dysplasia Scope and Market Size
Bronchopulmonary Dysplasia market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bronchopulmonary Dysplasia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Surfactant Replacement Therapy
Oxygen Therapy
Supportive Therapy
Others

Segment by Application
Clinic
Hospital
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Chiesi Farmaceutici
Discovery Laboratories
Takeda Pharmaceutical Company
MediPost
Clarassance
Syntrix Biosystems